Wild type and YMDD variant of hepatitis B virus: No difference in viral kinetics on lamivudine/tenofovir therapy in HIV–HBV co-infected patients

Prolonged lamivudine therapy has been identified as the major risk for the development of resistance in HBV, with rates of 90% after 4 years of treatment. Tenofovir disoproxil fumarate showed activity against both wild type and lamivudine resistant HBV in HIV–HBV co-infected patients. In order to co...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical virology 2006-05, Vol.36 (1), p.60-63
Main Authors: de Vries-Sluijs, T.E.M.S., van der Eijk, A.A., Hansen, B.E., Osterhaus, A.D.M.E., de Man, R.A., van der Ende, M.E.
Format: Article
Language:English
Subjects:
Adenine - analogs & derivatives
Adenine - therapeutic use
Adult
Anti-HIV Agents - therapeutic use
Biological and medical sciences
DNA, Viral - blood
Drug Resistance, Viral - genetics
Fundamental and applied biological sciences. Psychology
Genetic Variation
HBV
Hepatitis B - complications
Hepatitis B - drug therapy
Hepatitis B virus
Hepatitis B virus - drug effects
Hepatitis B virus - genetics
HIV
HIV Infections - complications
HIV Infections - drug therapy
Human immunodeficiency virus
Human viral diseases
Humans
Infectious diseases
Kinetics
Lamivudine
Lamivudine - therapeutic use
Male
Medical sciences
Microbiology
Middle Aged
Miscellaneous
Organophosphonates - therapeutic use
RNA, Viral - blood
Tenofovir
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral dynamics
Virology
YMDD
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prolonged lamivudine therapy has been identified as the major risk for the development of resistance in HBV, with rates of 90% after 4 years of treatment. Tenofovir disoproxil fumarate showed activity against both wild type and lamivudine resistant HBV in HIV–HBV co-infected patients. In order to compare the efficacy of lamivudine/tenofovir treatment we investigated detailed HBV kinetics in 13 HIV–HBV co-infected patients with either wild type HBV or lamivudine resistant HBV. The viral strains in both patient groups showed a biphasic viral decline pattern. Only in the first phase of viral decay, which reflects the clearance rate of the free virus from plasma, there was a statistically significant response in favor of the wild type group. After the first phase we observed a similar viral decline till 24 weeks of both groups. This is reassuring for many pretreated co-infected patients harbouring mutant viruses.
ISSN:1386-6532
1873-5967
DOI:10.1016/j.jcv.2005.12.004